Pipeline
The Science
About us
Investors
News

Hit enter to search or ESC to close

Prana Biotechnology Investor Presentation

June 27, 2018 Kerry Rowe

1_Prana Biotechnology Investor Presentation_2018-0627 final

Post navigation

Prana to commence Phase 1 clinical trial of PBT434 for treatment of parkinsonian diseases

First volunteers dosed in Phase I clinical trial of PBT434, Prana’s lead therapy for parkinsonian diseases

Related Posts

Prana Biotechnology Investor Presentation and Audio Recording – Phase 2 HD trial

February 18, 2014

Prana’s Founding Scientist and CSA publishes landmark paper in Nature

October 12, 2014

Prana Completes Phase 2 Huntington Disease Trial with PBT2

October 6, 2013

Recent Posts

Alterity CEO David Stamler presents to US investors at the HC Wainwright Global Life Science Conference
Alterity to present at the 7th International Congress of Multiple System Atrophy
Alterity Half Year Results and Investor Webcast Notification
Alterity announces funding from Michael J. Fox Foundation for ATH434 dose optimization for Parkinson’s disease clinical trials
Quarterly Cash Flow Report

Recent Comments

Archives

Archives

Categories

ASX Announcements
Investor Announcement

About us

We exist to create an alternate future for people living with neurodegenerative diseases. An alternate, healthier life. We’re here to disrupt the trajectory the world has come to accept for people with these diseases.
Improving lives.

Pipeline
The Science
About us
Investors
News

Careers
Privacy Policy

Copyright © Alterity Therapeutics. ABN 37 080 699 065